PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
Speakeasy Dispensary is excited to announce its new medical cannabis dispensary opening in Bowling Green on June 5! This move will enhance access for patients all across South Central Kentucky as the state's medical cannabis program continues to expand.
A new study published in the Journal of Experimental Biology suggests that mosquitoes can actually learn to be attracted to DEET, a common ingredient used in insect repellents. DEET, also known by its chemical name, N-diethyl-meta-toluamide, is widely used around the world to protect people from mosquito...
World Health Organization Chief Tedros Adhanom Ghebreyesus arrived in Kinshasa, the capital of Congo, late Thursday to review efforts to control an outbreak of a rare strain of Ebola. "To come here is to really show to the community that they're not alone," WHO Director-General Tedros Adhanom Ghebreyesus...
Replimune Group, Inc. (REPL) presented landmark three-year overall survival data from its IGNYTE clinical trial of RP1 plus Nivolumab in patients with anti-PD-1 failed melanoma at the 2026 ASCO annual meeting.